相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Assessment of Topoisomerase II α Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization
Atocha Romero et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial
F. P. O'Malley et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
M. Martin et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Multifactorial Approach to Predicting Resistance to Anthracyclines
Christine Desmedt et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy
Michael F. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
Angelo Di Leo et al.
LANCET ONCOLOGY (2011)
ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
Jan C. Brase et al.
CLINICAL CANCER RESEARCH (2010)
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
John M. S. Bartlett et al.
LANCET ONCOLOGY (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer
A. Rody et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study
Laura G. Estevez et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2009)
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
Joseph A. Sparano et al.
CLINICAL CANCER RESEARCH (2009)
TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance
Nathalie Wong et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013
Lyndsay N. Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
F. P. O'Malley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Expression of Human DNA Topoisomerase II-α in Squamous Cell Carcinoma of the Larynx and Its Correlation With Clinicopathologic Variables
Jacob Shvero et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
John M. S. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
Alessandra Gennari et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
Edurne Arriola et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular subtypes of breast cancer and amplification of topoisomerase IIα:: predictive role in dose intensive adjuvant chemotherapy
J. Hannemann et al.
BRITISH JOURNAL OF CANCER (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:: Scandinavian Breast Group Trial 9401
Minna Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy
KI Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
AS Knoop et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
M De Laurentiis et al.
CLINICAL CANCER RESEARCH (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
c-erbB2 and topoisomerase II alpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study
P Fritz et al.
BREAST CANCER RESEARCH (2005)
Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIα mutant human cell line
AJ Carpenter et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
T Petit et al.
EUROPEAN JOURNAL OF CANCER (2004)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes
KE Olsen et al.
ACTA ONCOLOGICA (2004)
Cellular roles of DNA topoisomerases: A molecular perspective
JC Wang
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Dynamics of human DNA topoisomerases IIα and IIβ in living cells
MO Christensen et al.
JOURNAL OF CELL BIOLOGY (2002)
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
S Paik et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Cell cycle-coupled variation in topoisomerase IIα mRNA is regulated by the 3′-untranslated region -: Possible role of redox-sensitive protein binding in mRNA accumulation
PC Goswami et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer
L Nakopoulou et al.
PATHOBIOLOGY (2000)
Topoisomerase IIα expression in breast cancer:: Correlation with outcome variables
PL Depowski et al.
MODERN PATHOLOGY (2000)
分享论文
